Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined immune responses to Diphencyprone and found that its induced skin reactions have higher levels of negative immune regulators compared to psoriasis, suggesting differences in immune regulation may contribute to psoriasis chronicity.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This review discusses the cutaneous symptoms associated with COVID-19 and their potential use in diagnosing and assessing the severity of the disease, but it reports no new clinical results.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review explores how air pollutants may contribute to various skin diseases and highlights potential mechanisms, but it presents no new clinical findings.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This review describes skin manifestations and reactions related to COVID-19 and COVID-19-related lifestyle changes but does not include new clinical data.

This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.

This review explores the impact of various medications on male fertility, highlighting reversible negative effects from methotrexate, finasteride, and ketoconazole, while reporting no adverse fertility effects for oral retinoids and certain immunosuppressants.

This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

This study suggests that COVID-19 infection may trigger telogen effluvium, a condition of hair shedding, though medication side effects and pandemic-related stress cannot be excluded as contributing factors.

This study observed a significant increase in certain dermatologic conditions a month and two months after the onset of the COVID-19 pandemic in Turkey, which may suggest a link with asymptomatic COVID-19 infection.

This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.

In this study, individuals reported a decrease in dermatologist visits for hair and scalp conditions like telogen effluvium and alopecia areata during COVID-19 quarantine, despite increased occurrences.

This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.

This article is a letter to the editor discussing the treatment of telogen effluvium using a dietary supplement, but it provides no new research results.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

This study found that 78% of patients continued taking oral minoxidil for androgenetic or traction alopecia, with 33% reporting decreased hair shedding and 28% noting increased scalp hair.

In this study, TCA peel was found to be the most effective treatment for stable non-segmental vitiligo among the modalities tested, and it increased both MMP-9 and IL-17 tissue levels.

This case series reports telogen effluvium in three patients following severe Sars-Cov-2 infection and suggests a potential association that merits further investigation.

This study observed increased online searches for "acne," "eczema," and "hair loss" but decreased interest in "botox," "skin cancer," and some other terms during the COVID-19 pandemic in Turkey and Italy.

This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This systematic review reports that for patients with underlying dermatologic disorders who contracted COVID-19, most experienced mild to moderate exacerbation of their skin conditions and were managed similarly to the general population, suggesting treatment discontinuation during acute infection may prevent severe recurrence.

Quarantine stress likely worsened hair loss in women, but video consultations helped manage their condition and reduce anxiety.

This report describes two patients with atopic dermatitis receiving dupilumab, where one experienced healing of alopecia areata and the other developed it, illustrating the drug's varied effects.

In this study, a patient with lichen planopillaris experienced complete resolution of itching and hair shedding following treatment with a new platelet-rich plasma regimen, marking the first reported success in this context.

This study found that combining topical and oral pulse corticosteroid therapy for severe alopecia areata in children led to long-lasting hair regrowth, especially in AA plurifocalis, with no serious side effects reported.